23 pending office actions • 17 clients
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 19342217 | CAPSID POLYPEPTIDES AND METHODS OF USE THEREOF | Dyno Therapeutics, Inc. | MARVICH, MARIA | 1634 | Non-Final OA | Sep 26, 2025 |
| 19317328 | T-CELL EXPANSION METHOD AND USES | Neogap Therapeutics AB | JUEDES, AMY E | 1644 | Non-Final OA | Sep 03, 2025 |
| 18700066 | NANOPARTICULATE FORMULATION | Newimmune Ii, LLC | GULLEDGE, BRIAN M | 1699 | Non-Final OA | Apr 10, 2024 |
| 18615334 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF HYPERCYTOKINEMIA AND SEVERE INFLUENZA | Poolbeg Pharma (Uk) Limited | RAHMANI, NILOOFAR | 1691 | Non-Final OA | Mar 25, 2024 |
| 18417702 | TREATMENT OF COMPLEMENT-MEDIATED DISORDERS | The Sydney Children's Hospitals Network | LEONARD, ARTHUR S | 1631 | Non-Final OA | Jan 19, 2024 |
| 18571367 | CAPSID VARIANTS AND METHODS OF USING THE SAME | Dyno Therapeutics, Inc. | CORNELIUS, CLAIRE ADRIENNE | 1672 | Non-Final OA | Dec 18, 2023 |
| 18570814 | PEPTIDE DRUG CONJUGATES | Oncopeptides Innovation AB | HEASLEY, MEGHAN CHRISTINE | 1626 | Non-Final OA | Dec 15, 2023 |
| 18548772 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | Go Therapeutics, Inc. | LU, CHENG | 1642 | Non-Final OA | Sep 01, 2023 |
| 18328327 | INTERLEUKIN-2 PROPROTEINS AND USES THEREOF | Regeneron Pharmaceuticals, Inc. | MERTZ, PREMA MARIA | 1674 | Non-Final OA | Jun 02, 2023 |
| 18316959 | ABCA4 TRANS-SPLICING MOLECULES | Ascidian Therapeutics, Inc. | NOBLE, MARCIA STEPHENS | 1632 | Non-Final OA | May 12, 2023 |
| 18247465 | METHODS FOR TREATING EYE DISEASES USING LIPID BINDING PROTEIN-BASED COMPLEXES | Abionyx Pharma SA | AUDET, MAURY A | 1654 | Non-Final OA | Mar 31, 2023 |
| 18042890 | IMPROVED DEPENDOPARVOVIRUS PRODUCTION COMPOSITIONS AND METHODS | Dyno Therapeutics, Inc. | PENNINGTON, KATIE LEIGH | 1634 | Non-Final OA | Feb 24, 2023 |
| 18003279 | IMMUNOTHERAPY | Neogap Therapeutics AB | JUEDES, AMY E | 1644 | Non-Final OA | Dec 23, 2022 |
| 17978647 | ANTIBIOTIC COMBINATION THERAPIES | BIOVERSYS AG | ESPINOSA, CLAUDIA EDILMA | 1654 | Final Rejection | Nov 01, 2022 |
| 17918641 | METHODS FOR TREATING ACUTE CONDITIONS USING LIPID BINDING PROTEIN-BASED COMPLEXES | Abionyx Pharma SA | COFFA, SERGIO | 1658 | Final Rejection | Oct 13, 2022 |
| 17887565 | IL27 RECEPTOR AGONISTS AND METHODS OF USE THEREOF | Regeneron Pharmaceuticals, Inc. | DONOGHUE, BRITTNEY ERIN | 1675 | Final Rejection | Aug 15, 2022 |
| 17717858 | RECOMBINANT AAV FOR TREATMENT OF NEURAL DISEASE | Affinia Therapeutics Inc. | CAMPBELL, KATRINA JO | 1675 | Non-Final OA | Apr 11, 2022 |
| 17620987 | DOSING REGIMEN AND COMBINATION THERAPIES FOR MULTISPECIFIC ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN | Novartis AG | NICKOL, GARY B | 1643 | Non-Final OA | Dec 20, 2021 |
| 17616246 | BREAST CANCER DETECTION METHODS | Cambridge Enterprise Limited | SULLIVAN, DENNIS JOHN | 1642 | Non-Final OA | Dec 03, 2021 |
| 17613898 | GLUCONATE DEHYDRATASE ENZYMES AND RECOMBINANT CELLS | BP CORPORATION NORTH AMERICA INC. | IANNUZO, NATALIE NMN | 1653 | Non-Final OA | Nov 23, 2021 |
| 17417601 | PHAGOCYTISABLE PARTICLE FOR USE IN THE TREATMENT OR PROPHYLAXIS OF CANCER | Neogap Therapeutics AB | JOHANSEN, PETER N. | 1644 | Final Rejection | Jun 23, 2021 |
| 17258889 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | Synthis Therapeutics, Inc. | ESSEX, LAURA ANN | 1675 | Non-Final OA | Jan 08, 2021 |
| 17055511 | BACTERIAL VECTORS FOR GENETIC MANIPULATION OF BACTERIA | BIOVERSYS AG | LIPPOLIS, ALEXANDRA ROSE | 1637 | Non-Final OA | Nov 13, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial